DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $262,285 | +131042.5% | 8,888 | +1.9% | 0.00% | 0.0% |
| Q1 2023 | $200 | -26.7% | 8,724 | -11.5% | 0.00% | 0.0% |
| Q4 2022 | $273 | -99.9% | 9,858 | -16.7% | 0.00% | -50.0% |
| Q3 2022 | $362,000 | +9.7% | 11,834 | +5.4% | 0.00% | 0.0% |
| Q2 2022 | $330,000 | -47.7% | 11,230 | -42.9% | 0.00% | -33.3% |
| Q1 2022 | $631,000 | -13.9% | 19,652 | +19.4% | 0.00% | 0.0% |
| Q4 2021 | $733,000 | -1.6% | 16,458 | +11.2% | 0.00% | -25.0% |
| Q3 2021 | $745,000 | +32.1% | 14,799 | +105.3% | 0.00% | +33.3% |
| Q2 2021 | $564,000 | +126.5% | 7,207 | +64.2% | 0.00% | +50.0% |
| Q1 2021 | $249,000 | +19.1% | 4,390 | +75.6% | 0.00% | 0.0% |
| Q4 2020 | $209,000 | +134.8% | 2,500 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $89,000 | – | 2,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |